A novel cell-penetrating peptide, Tat-SIRT5-CTM, has been developed to selectively induce lysosomal degradation of SIRT5 in microglia, thereby mitigating microglia-driven neuroinflammation after ischemic stroke. The gene discussed is HSF4; the disease is ischemic stroke.